BETHESDA, MD--(Marketwire - September 06, 2012) -
Peter Greenleaf, president of MedImmune, the Gaithersburg, Maryland-based global biologics arm of AstraZeneca, addressed many of the challenges and growth opportunities for Maryland biotech companies at today's MdBio Leadership Series breakfast, hosted by the Tech Council of Maryland (TCM).
"Maryland is a hotbed of activity in the biotech sector, so changes taking place in the industry -- related to competitive threats and growth opportunities -- will no doubt have a big impact on businesses based in our state," said Art Jacoby, TCM's CEO. "Peter's remarks this morning provided valuable insight -- from not only his role as president of MedImmune, but from the perspective as chairman of the Maryland Venture Fund Authority -- into the changes taking place in the biotech market and how companies at all stages can position themselves for success."
More than 200 attendees at the MdBio Leadership breakfast today heard Greenleaf discuss a host of issues, ranging from the global economy and the macro-economic factors driving long-term growth to the challenges associated with early-stage funding for biotech companies. He also underscored the importance of the biotechnology industry evolving its R&D efforts and focusing on collaborations and partnerships to ensure that innovative drugs demonstrate value and make it to market in a timely manner.
Greenleaf then discussed the InvestMaryland program, which plays a vital role in strengthening the life sciences market in the state. He noted that InvestMaryland will help foster pipeline development by funding early, mid and late stage companies.
TCM's MdBio Leadership Series provides programs that cover a broad range of topics focused on the latest trends in both science and business as they pertain to this industry. The breakfasts are attended by biotechnology and life science executives, business development and technical professionals, as well as representatives from government, academia and the service provider industry. In addition to Greenleaf, past speakers have included Margaret Hamburg, M.D., Commissioner of the U.S. Food and Drug Administration; and a panel on Big Pharma.
ABOUT THE TECH COUNCIL OF MARYLAND, INC.
The Tech Council of Maryland (TCM) is the largest technology trade group serving the advanced technology and biotechnology communities of Maryland. TCM's mission is to advocate for the interests of the technology community, further the role of technology in the Maryland economy, and nurture an environment where technology companies can collaborate, grow and succeed. For more information, visit www.techcouncilmd.com.